Sanofi's Wayrilz Receives Orphan Drug Designation for IgG4-Related Disease in Japan

Waylirz Receives Orphan Drug Status in Japan

Sanofi’s investigational therapy, Waylirz (rilzabrutinib), has been granted orphan drug status by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of IgG4-related disease (IgG4-RD). At present, this medication has not been authorized for this use in any country.

Implications of Orphan Drug Designation for Sanofi

The MHLW awards orphan drug designation to treatments aimed at rare conditions that impact fewer than 50,000 individuals in Japan. This designation is intended to stimulate the development of medicines for rare diseases by providing benefits such as expedited consultations, tax incentives, financial support, and priority in the review process.

For Sanofi, this recognition offers significant regulatory and financial support as Waylirz progresses through clinical trials for IgG4-RD—a rare disorder that can affect multiple organs and potentially cause lasting organ damage if untreated. The orphan status is expected to help speed up development and lessen regulatory hurdles as Sanofi seeks to address this unmet medical need.

This is the third time rilzabrutinib has received orphan drug designation for IgG4-RD, following similar recognitions in the United States and the European Union.

About Waylirz

Waylirz is a new BTK inhibitor developed to treat various rare immune-mediated and inflammatory conditions by modulating the immune system. It is currently approved for immune thrombocytopenia (ITP) in both the United States and Europe, and a similar application is under review in Japan.

The decision by the MHLW to grant orphan status for IgG4-RD was based on encouraging results from a phase 2 clinical trial, which demonstrated that 52 weeks of treatment led to fewer disease flare-ups, improved disease markers, and reduced reliance on glucocorticoids.

Sanofi is now conducting advanced clinical studies of Waylirz for IgG4-RD, sickle cell disease (SCD), and warm autoimmune hemolytic anemia (wAIHA). Additionally, the drug is being tested in mid-stage trials for asthma and chronic spontaneous urticaria (CSU).

Competitive Landscape for Waylirz

Waylirz faces competition in several of its intended treatment areas, with the level of competition differing by disease and development phase.

• For ITP, Waylirz competes with Amgen’s Nplate and Rigel Pharmaceuticals’ Tavalisse. Although these rival drugs use different mechanisms, they present strong competition for Waylirz, which is newer to the market.
• If approved for IgG4-RD, Waylirz may compete with existing therapies such as Amgen’s Uplizna.
• In the CSU space, Waylirz would go up against Dupixent, a leading therapy co-marketed by Sanofi and Regeneron, which already holds a significant share in the immunology market.

The Next Phase of AI Investment

The artificial intelligence sector has already created substantial wealth, but the most well-known companies may not offer the highest returns going forward. Emerging AI firms that are addressing major global challenges could present more attractive opportunities in the near future.

Additional Resources